Is Crohn’s Disease Cancer? Differences and Real Risks

Crohn’s disease is not cancer. It is a chronic inflammatory condition of the digestive tract, and while it shares some superficial features with cancer, such as abnormal tissue growth and the potential need for surgery, the two diseases arise from fundamentally different processes. That said, living with Crohn’s does carry a real, measurable increase in the risk of developing certain cancers over time. A 30-year follow-up study found that people with Crohn’s were roughly 1.6 times more likely to be diagnosed with cancer than matched controls from the general population.¹ Understanding where that extra risk comes from, which cancers to watch for, and what you can do about it matters more than the headline number.

How Crohn’s Disease and Cancer Differ

Crohn’s disease is an autoimmune-type disorder in which the immune system attacks the lining of the digestive tract, causing chronic inflammation that can affect anywhere from the mouth to the anus. It tends to flare and remit. Cancer, by contrast, involves cells that have escaped the body’s normal growth controls, multiplying without restraint and sometimes spreading to distant organs. The two are biologically different: Crohn’s does not involve malignant cells, and having Crohn’s does not mean cancer is developing. However, the persistent inflammation that defines Crohn’s can, over years or decades, create conditions in the gut lining that make cancerous changes more likely. The diseases are distinct, but they are connected.

How Chronic Inflammation Drives Cancer Risk

The elevated cancer risk in Crohn’s is not random bad luck. It is driven by the same chronic inflammation that causes the disease’s symptoms. During active disease, the immune system floods the intestinal lining with inflammatory signals. Those signals do several things at once that, over time, tilt the odds toward cancerous changes.

First, inflammatory cells release reactive oxygen and nitrogen species, which are chemically unstable molecules that can directly damage DNA. These molecules can hit critical genes involved in tumor suppression, including p53 and genes responsible for repairing mismatches in DNA.² When those repair systems are impaired, mutations accumulate. Second, the inflammatory environment activates survival pathways inside intestinal cells, making damaged cells less likely to self-destruct through normal programmed cell death. Third, the same inflammatory signals promote the growth of new blood vessels and create a tissue environment that supports tumor spread.³ In short, ongoing inflammation acts as a fertilizer for cancer at every stage: it helps start mutations, helps mutated cells survive, and helps early tumors grow.

The gut microbiome plays a supporting role. In Crohn’s, the balance of intestinal bacteria is often disrupted, and this imbalance can independently promote genetic and epigenetic changes in the colon lining that push cells toward malignant transformation.⁴

Colorectal Cancer in Crohn’s

Colorectal cancer is the cancer most commonly associated with inflammatory bowel disease, and the risk is driven largely by how much of the colon is inflamed and for how long. People whose Crohn’s affects a large portion of the colon, sometimes called extensive Crohn’s colitis, face a substantially higher risk. One study found an 18-fold increase in colorectal cancer risk in patients with extensive Crohn’s colitis compared to the general population, with a cumulative risk of about 8% at 22 years after symptom onset.⁵ That same study found a strikingly similar risk profile in ulcerative colitis patients with extensive disease, reinforcing the idea that chronic inflammation itself, rather than anything unique to either diagnosis, is the primary driver.

A separate analysis comparing colorectal cancers in Crohn’s and ulcerative colitis found that the cancers arising in both conditions looked very similar: they tended to develop in the area of active disease, appeared after more than eight years of illness in the majority of patients, and showed comparable rates of aggressive histological features and five-year survival.⁶ The practical implication is straightforward: if your Crohn’s involves a significant portion of the colon, your colorectal cancer surveillance needs are similar to those of someone with extensive ulcerative colitis.

Several factors push that risk higher: longer disease duration, more severe or persistent inflammation, the presence of inflammatory pseudopolyps, a coexisting liver condition called primary sclerosing cholangitis, and a family history of colorectal cancer.⁷ The duration effect is one reason surveillance colonoscopies typically begin about eight to ten years after diagnosis in patients with colonic disease.

Small Bowel Cancer

While colorectal cancer gets the most attention, Crohn’s also increases the risk of cancer in the small intestine, a site that is rarely affected in people without inflammatory bowel disease. A large U.S. database study found that people with Crohn’s had nearly five times the risk of small bowel cancer compared to people without IBD.⁸ The ileum, the final stretch of the small intestine and the most common site of Crohn’s involvement, is where the vast majority of these cancers appear, affecting roughly 84% of patients with Crohn’s-related small bowel adenocarcinoma.⁹

Small bowel cancer in Crohn’s is rare in absolute terms, but it is notoriously difficult to detect. It tends to arise in segments of bowel that are already scarred, narrowed, and inflamed, which means symptoms like pain and obstruction can easily be mistaken for a Crohn’s flare rather than a new tumor.¹⁰ Diagnosis often comes late, and outcomes are generally poor. This is an area where heightened clinical suspicion matters: if you have long-standing ileal Crohn’s and develop new symptoms that feel different from your usual flares, it is worth flagging with your gastroenterologist.

Perianal Fistula-Related Cancer

Perianal fistulas are one of the more debilitating complications of Crohn’s disease, and they carry their own cancer risk. Cancer arising in the setting of a chronic perianal fistula is rare but well-documented. A systematic review characterized it as typically a squamous cell carcinoma developing at the fistula site.¹¹

A Danish cohort study quantified the risk more precisely and found that people with Crohn’s disease and anorectal fistulas had roughly a three-fold increased risk of anorectal cancer compared to the general population. The increase was particularly dramatic for anal cancer specifically, where the risk was about 15 times higher than in people without IBD. On average, the cancer appeared around seven years after the fistula was diagnosed.¹² A French cohort study reported broadly consistent numbers, with incidence rates of 0.26 per 1,000 patient-years for anal squamous cell carcinoma and 0.38 per 1,000 for perianal fistula-related adenocarcinoma among patients with perianal Crohn’s lesions.¹³ These numbers are still small in absolute terms, but they make a case for close monitoring of long-standing perianal fistulas, especially ones that are not healing or are changing in character.

Cancers Outside the Gut

The cancer risk in Crohn’s is not confined to the digestive tract. A large meta-analysis of population-based studies found that people with Crohn’s had about a 2.4-fold increased risk of blood cancers, including lymphoma and leukemia, and about a 1.5-fold increased risk of lung cancer.¹⁴ An earlier meta-analysis also identified elevated risks for cancers of the upper gastrointestinal tract, the urinary bladder, and the skin.¹⁵

The picture is not entirely settled, though. A Danish population-based cohort study found that extra-intestinal cancers did not occur more frequently than expected in Crohn’s patients.¹⁶ This discrepancy likely reflects differences in study populations, follow-up times, and the confounding influence of medications. Teasing apart whether the elevated rates of blood cancer and skin cancer come from Crohn’s itself or from the immunosuppressive drugs used to treat it is one of the persistent challenges in this field.

Do Crohn’s Medications Affect Cancer Risk

This question weighs on many patients, and the evidence is nuanced. The medications most scrutinized for cancer associations are thiopurines (azathioprine and 6-mercaptopurine) and biologic therapies targeting tumor necrosis factor (TNF).

For thiopurines, a large study found that azathioprine use was associated with about a 2.4-fold increased risk of lymphoid tissue cancers and roughly a 2.8-fold increased risk of urinary tract cancers.¹⁷ However, data from other populations tell a different story. A long-term cohort study from India, which followed over 250 patients on thiopurines for five or more years, found zero cases of lymphoma or non-melanoma skin cancer.¹⁸ Baseline cancer rates and genetic background likely influence these outcomes, which is why risk estimates from Western European populations cannot simply be applied worldwide.

For anti-TNF biologics like infliximab and adalimumab, initial concerns about lymphoma were significant. But a large study found that after adjusting for concurrent thiopurine use, anti-TNF therapy on its own did not significantly increase the risk of blood cancers.¹⁹ The concern that persists is about combination therapy: using both a thiopurine and an anti-TNF biologic together. Rare but aggressive lymphomas, including hepatosplenic T-cell lymphoma, have been reported primarily in young men on this dual therapy.²⁰ The overall safety profile of anti-TNF monotherapy is considered favorable, though it may carry a small increase in risk of skin cancer and serious infections.²¹

The practical reality is that uncontrolled inflammation itself is a cancer risk factor. Anti-inflammatory treatment, including these medications, may actually reduce long-term cancer risk by keeping inflammation suppressed. Some evidence suggests that agents like 5-aminosalicylate compounds and immune modulators could function as chemopreventive, precisely because they reduce the chronic inflammatory burden in the colon.²² Stopping effective therapy out of cancer fear can be counterproductive if it leads to more flares and more cumulative inflammation.

Cancer Screening When You Have Crohn’s

Screening colonoscopies are the backbone of cancer prevention in Crohn’s. Guidelines generally recommend starting surveillance colonoscopy about eight years after diagnosis in patients with colonic involvement, then repeating it at intervals determined by risk factors. The goal is to catch dysplasia, the precancerous tissue changes that precede colorectal cancer, early enough to intervene.

The technology for finding dysplasia has improved considerably. Older approaches relied on taking random tissue samples scattered across the colon, which inevitably missed flat or subtle lesions. Newer techniques, including high-definition white-light endoscopy and chromoendoscopy (where dye is sprayed on the colon lining to make abnormal patches more visible), have substantially improved detection rates.²³ Chromoendoscopy with targeted biopsies is now widely endorsed as the preferred surveillance technique for IBD patients.²⁴ If your gastroenterologist is still using random biopsies alone during surveillance colonoscopy, it is worth asking whether chromoendoscopy is available.

Screening for small bowel cancer remains far more challenging. There is no widely accepted surveillance protocol for Crohn’s-related small bowel malignancy, largely because the small intestine is difficult to image and the cancer is rare enough that mass screening would not be practical. Clinicians tend to rely on cross-sectional imaging like MRI or CT when new or changing symptoms raise suspicion.

Pediatric-Onset Crohn’s and Long-Term Cancer Risk

People diagnosed with Crohn’s in childhood face a longer lifetime of chronic inflammation, and this translates into a measurable increase in cancer risk. A meta-analysis of population-based studies found that pediatric-onset IBD was associated with about a 2.5-fold increased rate of cancer overall, with Crohn’s disease specifically showing about a two-fold increase.²⁵ A Danish cohort study confirmed a similar elevation and uncovered a strong sex difference: male patients with pediatric-onset IBD had nearly a four-fold increased cancer risk, while female patients had about a 1.5-fold increase.²⁶

This sex disparity echoes findings in adult Crohn’s populations, where the 30-year follow-up study mentioned earlier found that male patients were at significantly higher risk of cancer than their matched controls, while the increase in female patients did not reach statistical significance.¹ Why men with Crohn’s appear more cancer-prone than women with the same disease is not fully understood and remains an active area of investigation.

What Patients Often Get Wrong About Their Risk

There is a gap between perceived and actual cancer risk among people with Crohn’s and ulcerative colitis, and it skews in both directions. A study surveying IBD patients found that they estimated their 10-year colorectal cancer risk at 25% and their cancer-related mortality risk at 13%.²⁷ These numbers are considerably higher than what the evidence supports for most patients. Even in the highest-risk subgroup, those with extensive colitis of very long duration, the cumulative colorectal cancer risk at 22 years was about 8%.⁵ For the majority of Crohn’s patients, especially those without extensive colonic disease, the absolute risk is lower still.

Overestimating risk is not harmless. It can lead to anxiety, avoidance of necessary treatments, and a general sense that cancer is inevitable rather than preventable. On the other side, some patients assume that Crohn’s limited to the small bowel carries no cancer risk at all, which is also incorrect given the elevated small bowel cancer rates discussed above. The most useful framing is that Crohn’s raises cancer risk modestly, that the risk concentrates in specific areas depending on where the disease is active, and that surveillance and effective disease control are the best tools available to keep that risk manageable.

Managing Both Conditions at Once

When someone with Crohn’s does develop cancer, treatment becomes a balancing act. Many of the drugs used to control Crohn’s, particularly immunosuppressants and biologics, can theoretically promote tumor growth or interfere with cancer therapies. At the same time, withdrawing those medications risks triggering a severe Crohn’s flare, which can complicate cancer treatment or make the patient too sick for chemotherapy. Current recommendations emphasize a case-by-case approach involving both a gastroenterologist and an oncologist, because the evidence base for managing these overlapping conditions is thin and general rules often do not apply to individual patients.²⁸ The decisions around whether to continue, pause, or switch IBD medications during and after cancer treatment are among the most difficult in gastroenterology, and they remain an area where more research is badly needed.